658 related articles for article (PubMed ID: 19423543)
21. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.
McKinnell JA; Patel M; Shirley RM; Kunz DF; Moser SA; Baddley JW
Epidemiol Infect; 2011 Sep; 139(9):1342-50. PubMed ID: 21073764
[TBL] [Abstract][Full Text] [Related]
22. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
23. Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia.
McComb MN; Collins CD
Pharmacotherapy; 2014 Jun; 34(6):537-44. PubMed ID: 24390863
[TBL] [Abstract][Full Text] [Related]
24. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
Patel R; Gallagher JC
Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
[TBL] [Abstract][Full Text] [Related]
25. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
26. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci.
Scheetz MH; Qi C; Noskin GA; Warren JR; Postelnick MJ; Malczynski M; Huang J; Zembower TR
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):407-13. PubMed ID: 16930924
[TBL] [Abstract][Full Text] [Related]
27. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
29. Optimizing therapy for vancomycin-resistant enterococci (VRE).
Linden PK
Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome.
Han SH; Chin BS; Lee HS; Jeong SJ; Choi HK; Kim CO; Yong D; Choi JY; Song YG; Lee K; Kim JM
J Infect; 2009 Mar; 58(3):182-90. PubMed ID: 19233476
[TBL] [Abstract][Full Text] [Related]
31. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid.
Wareham DW; Abbas H; Karcher AM; Das SS
J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU].
Álvarez-Lerma F; Palomar Martínez M; Olaechea Astigarraga P; Insausti Ordeñana J; López Pueyo MJ; Gracia Arnillas MP; Gimeno Costa R; Seijas Betolaza I
Rev Esp Quimioter; 2012 Mar; 25(1):65-73. PubMed ID: 22488544
[TBL] [Abstract][Full Text] [Related]
33. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
34. Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus.
Patel K; Kabir R; Ahmad S; Allen SL
J Oncol Pharm Pract; 2016 Apr; 22(2):212-8. PubMed ID: 25326010
[TBL] [Abstract][Full Text] [Related]
35. [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)].
Lübbert C; Wilhelms D; Worlitzsch D; Ettrich TJ; Behl S; Seufferlein T
Z Gastroenterol; 2012 Apr; 50(4):373-81. PubMed ID: 22430297
[TBL] [Abstract][Full Text] [Related]
36. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
[TBL] [Abstract][Full Text] [Related]
37. Endocarditis due to vancomycin-resistant Enterococcus raffinosus successfully treated with linezolid: case report and review of literature.
Jasovich A; Ganaha MC; Ebi C; García RD; Blanco MA; Lopardo H
Rev Argent Microbiol; 2008; 40(4):204-7. PubMed ID: 19213241
[TBL] [Abstract][Full Text] [Related]
38. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.
Segreti JA; Crank CW; Finney MS
Pharmacotherapy; 2006 Mar; 26(3):347-52. PubMed ID: 16503714
[TBL] [Abstract][Full Text] [Related]
39. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation.
Kapur D; Dorsky D; Feingold JM; Bona RD; Edwards RL; Aslanzadeh J; Tutschka PJ; Bilgrami S
Bone Marrow Transplant; 2000 Jan; 25(2):147-52. PubMed ID: 10673672
[TBL] [Abstract][Full Text] [Related]
40. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
